Eva Hua

424 total citations
13 papers, 84 citations indexed

About

Eva Hua is a scholar working on Rheumatology, Pathology and Forensic Medicine and Pharmacology. According to data from OpenAlex, Eva Hua has authored 13 papers receiving a total of 84 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Rheumatology, 8 papers in Pathology and Forensic Medicine and 3 papers in Pharmacology. Recurrent topics in Eva Hua's work include Urticaria and Related Conditions (10 papers), Autoimmune Bullous Skin Diseases (7 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (3 papers). Eva Hua is often cited by papers focused on Urticaria and Related Conditions (10 papers), Autoimmune Bullous Skin Diseases (7 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (3 papers). Eva Hua collaborates with scholars based in Switzerland, China and United States. Eva Hua's co-authors include Marcus Maurer, Jonathan A. Bernstein, Petra Staubach, Thomas Severin, Karl Sitz, Avantika Barve, Weily Soong, Gordon Sussman, Sinisa Savic and Martin Metz and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Allergy and Pharmaceutics.

In The Last Decade

Eva Hua

12 papers receiving 84 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eva Hua Switzerland 5 67 35 27 24 23 13 84
André Ellrich Germany 3 89 1.3× 40 1.1× 38 1.4× 11 0.5× 49 2.1× 4 96
José Ignacio Larco Ecuador 3 22 0.3× 11 0.3× 39 1.4× 9 0.4× 6 0.3× 8 66
Mojca Bizjak Slovenia 8 127 1.9× 43 1.2× 42 1.6× 2 0.1× 44 1.9× 17 160
Jaison Jose United States 5 13 0.2× 7 0.2× 23 0.9× 8 0.3× 6 0.3× 7 60
Hanneke N.G. Oude Elberink Netherlands 6 37 0.6× 5 0.1× 5 0.2× 34 1.4× 46 2.0× 15 126
Bernadetta Majorek‐Olechowska Poland 3 14 0.2× 9 0.3× 10 0.4× 10 0.4× 3 0.1× 5 25
Guillaume Bayer France 2 10 0.1× 12 0.3× 8 0.3× 2 0.1× 9 0.4× 2 32
Yervand Hakobyan Armenia 4 47 0.7× 5 0.1× 32 1.2× 11 0.5× 9 0.4× 13 66
Kåre Steinar Tveit Norway 5 18 0.3× 9 0.3× 13 0.5× 39 1.7× 8 72
Miklos Perenyei United Kingdom 3 5 0.1× 8 0.2× 4 0.1× 4 0.2× 7 0.3× 9 49

Countries citing papers authored by Eva Hua

Since Specialization
Citations

This map shows the geographic impact of Eva Hua's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Hua with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Hua more than expected).

Fields of papers citing papers by Eva Hua

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Hua. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Hua. The network helps show where Eva Hua may publish in the future.

Co-authorship network of co-authors of Eva Hua

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Hua. A scholar is included among the top collaborators of Eva Hua based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Hua. Eva Hua is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Takahashi, Hidetoshi, Atsushi Fukunaga, Koremasa Hayama, et al.. (2024). Long term safety and efficacy of ligelizumab in the treatment of Japanese patients with chronic spontaneous urticaria. Allergology International. 74(1). 136–143. 1 indexed citations
2.
Vandemeulebroecke, Marc, et al.. (2024). New strategies for confirmatory testing of secondary hypotheses on combined data from multiple trials. Clinical Trials. 21(2). 171–179. 1 indexed citations
3.
Bernstein, Jonathan A., Ana M. Giménez‐Arnau, Marcus Maurer, et al.. (2023). Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria. Journal of Clinical Medicine. 12(10). 3561–3561. 8 indexed citations
4.
Staubach, Petra, Montserrat Álvaro‐Lozano, Bülent Enis Şekerel, et al.. (2023). Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis. Pediatric Allergy and Immunology. 34(7). e13982–e13982. 12 indexed citations
5.
6.
Ensina, Luís Felipe, Jonathan A. Bernstein, Gordon Sussman, et al.. (2023). Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria: Results from the Phase-3 Pivotal Trials. Journal of Allergy and Clinical Immunology. 151(2). AB130–AB130. 5 indexed citations
7.
Giménez‐Arnau, Ana M., Marcus Maurer, Jonathan A. Bernstein, et al.. (2022). Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria. Clinical and Translational Allergy. 12(2). e12121–e12121. 12 indexed citations
8.
Metz, Martin, Jonathan A. Bernstein, Ana M. Giménez‐Arnau, et al.. (2022). Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria. World Allergy Organization Journal. 15(11). 100716–100716. 4 indexed citations
9.
Maurer, Marcus, Ana M. Giménez‐Arnau, Jonathan A. Bernstein, et al.. (2021). Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one‐year extension study. Allergy. 77(7). 2175–2184. 29 indexed citations
10.
Hua, Eva, et al.. (2021). A Phase 3 Trial Analysis Proposal for Mitigating the Impact of the COVID-19 Pandemic. Statistics in Biopharmaceutical Research. 14(1). 80–86. 4 indexed citations
11.
Soong, Weily, Jonathan A. Bernstein, Gordon Sussman, et al.. (2020). Long-term treatment with ligelizumab achieves prolonged symptom control during the post-treatment follow-up. Journal of Allergy and Clinical Immunology. 145(2). AB341–AB341. 3 indexed citations
12.
Sitz, Karl, Weily Soong, Bob Lanier, et al.. (2019). P153 LIGELIZUMAB REDUCES RESCUE MEDICATION USE IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: PHASE 2B STUDY RESULTS. Annals of Allergy Asthma & Immunology. 123(5). S28–S28. 3 indexed citations
13.
Soong, Weily, Bob Lanier, Karl Sitz, et al.. (2019). P151 LIGELIZUMAB ACHIEVES SUSTAINED CONTROL OF ANGIOEDEMA IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA. Annals of Allergy Asthma & Immunology. 123(5). S27–S27. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by André Ellrich Breakdown of academic impact, for papers by José Ignacio Larco Breakdown of academic impact, for papers by Mojca Bizjak Breakdown of academic impact, for papers by Jaison Jose Breakdown of academic impact, for papers by Hanneke N.G. Oude Elberink Breakdown of academic impact, for papers by Bernadetta Majorek‐Olechowska Breakdown of academic impact, for papers by Guillaume Bayer Breakdown of academic impact, for papers by Yervand Hakobyan Breakdown of academic impact, for papers by Kåre Steinar Tveit Breakdown of academic impact, for papers by Miklos Perenyei
Rankless by CCL
2026